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Abstract
Background
It is cost-effective to perform an HIV test in people with specific indicator conditions (IC) with
an undiagnosed HIV prevalence of at least 0.1%. Our aim was to determine the HIV preva-
lence for 14 different conditions across 20 European countries.
Methods
Individuals aged 18–65 years presenting for care with one of 14 ICs between January 2012
and June 2014 were included and routinely offered an HIV test. Logistic regression
assessed factors associated with testing HIV positive. Patients presenting with infectious
mononucleosis-like syndrome (IMS) were recruited up until September 2015.
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Results
Of 10,877 patients presenting with an IC and included in the analysis, 303 tested positive
(2.8%; 95% CI 2.5–3.1%). People presenting with an IC in Southern and Eastern Europe
were more likely to test HIV positive as were people presenting with IMS, lymphadenopathy
and leukocytopenia/ thrombocytopenia. One third of people diagnosed with HIV after pre-
senting with IMS reported a negative HIV test in the preceding 12 months. Of patients newly
diagnosed with HIV where data was available, 92.6% were promptly linked to care; of these
10.4% were reported lost to follow up or dead 12 months after diagnosis.
Conclusion
The study showed that 10 conditions had HIV prevalences > 0.1%. These 10 ICs should be
adopted into HIV testing and IC specialty guidelines. As IMS presentation can mimic acute
HIV sero-conversion and has the highest positivity rate, this IC in particular affords opportu-
nities for earlier diagnosis and public health benefit.
Introduction
The HIDES 1 study (HIV Indicator Diseases across Europe Study) gave proof of concept that
Indicator Condition (IC) guided HIV testing is an acceptable, feasible and effective strategy to
diagnose people living with HIV in health care setting encounters [1]. Identification of ICs
that should prompt a routine offer of an HIV test in all health care settings is based on their
classification into three categories; conditions which are AIDS defining among people living
with HIV (Category 1); conditions with a proven HIV prevalence� 0.1% (Category 2a) or
expected to do so (Category 2b) and conditions where not identifying HIV infection can have
significant adverse implications for the management of the patient (e.g. chemotherapy; Cate-
gory 3). The 0.1% threshold for Category 2 is based on studies suggesting that HIV testing is
cost-effective when the undiagnosed HIV prevalence in the tested population is at least 0.1%
[2–3]. The implementation of this strategy is further described in the Guidance for Implement-
ing HIV Testing in Adults in Health Care Settings developed for the European Region [4–5].
The pilot study HIDES 1, which informed the guidance evidence base, demonstrated eight of
the ICs studied fulfilled the study’s criteria having an HIV prevalence of� 0.1%, i.e. sexually
transmitted infections (STI), malignant lymphoma, irrespective of type (LYM), cervical or anal
cancer/dysplasia (CAN), hepatitis B or C virus infection (HEP), herpes zoster (HZV), ongoing
infectious mononucleosis-like syndrome (IMS), unexplained leukocytopenia/thrombocytope-
nia lasting >4 weeks (CYT), seborrheic dermatitis/exanthema (SEB). An audit of HIV testing
in tuberculosis (TB), candida oesophagitis (OC), non-Hodgkin’s lymphoma (NHL), anal can-
cer (AC) cervical cancer (CC) and hepatitis B and C (HEP) across Europe was conducted in
parallel and is reported elsewhere [6]; this demonstrated poor performance of IC guided test-
ing in people presenting with well recognised AIDS-defining and non-AIDS defining indicator
conditions.
The aim of this second phase of the study, HIDES II, was to expand the testing strategy by
increasing the number of both ICs and participating centres to determine the HIV prevalence
for 14 different conditions across Europe and thereby further refining the evidence for Cate-
gory 2 ICs. Secondary outcomes included CD4 count and disease stage at diagnosis and access
to care for those individuals testing HIV positive.
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Methods
Thirteen ICs were selected for determination of undiagnosed HIV prevalence. Individuals
aged 18–65 years, not known to be HIV positive and presenting for care with one of the 14 ICs
listed below between January 2012 and June 2014 were included:
• malignant lymphoma (irrespective of type)
• cervical dysplasia or cancer (CIN II and above)
• anal dysplasia or cancer
• hepatitis B infection (HBV, acute or chronic; irrespective of when diagnosed)
• hepatitis C infection (HCV, acute or chronic; irrespective of when diagnosed)
• both hepatitis B and C infection (acute or chronic; irrespective of when diagnosed)
• infectious mononucleosis-like syndrome (IMS)
• unexplained leukocytopenia or thrombocytopenia of at least 4 weeks duration
• seborrheic dermatitis/exanthema
• pneumonia, requiring hospital admission for at least 24 hours
• unexplained lymphadenopathy
• peripheral neuropathy of unknown cause (diagnosed by neurologist)
• primary lung cancer and
• severe or recalcitrant psoriasis (newly diagnosed).
Given the importance of infectious mononucleosis-like syndrome (IMS) as an IC in rela-
tion to recency of infection, transmission risk and high HIV prevalence the IMS arm was
extended until September 2015.
Recruitment was continued at sites involved in HIDES 1 [1], with additional sites recruited
by invitation through established contacts (full list of sites and settings in S1 Appendix). Ethical
approval was obtained where required in participating countries in line with National require-
ments. As HIV testing was performed routinely as part of the investigation of the IC, consent
to the test was obtained verbally where required (list of EC/IRB per country in S2 Appendix).
Consecutive patients were enrolled if they presented with the selected IC and were not already
known to be HIV positive. Patient inclusion was based on the treating physician’s clinical,
microbiological or histological diagnosis, or when the IC was part of the differential diagnosis.
Data were captured through the electronic submission system REDCap (Vanderbilt Univer-
sity, Nashville, USA) (HIDES patient enrolment form in S3 Appendix).
Individual’s characteristics were compared across regions using chi-squared tests for cate-
gorical variables and the Wilcoxon test for continuous variables. Clinics were grouped into
four regions, consistent with those used in the EuroSIDA study [7]; Southern Europe (Greece,
Italy, Spain, Israel), Central Europe (Belgium, France, Germany, Switzerland, Austria), North-
ern Europe (UK, Denmark, Netherlands) and Eastern Europe (Georgia, Belarus, Serbia,
Poland, Romania, Ukraine, Croatia, Bosnia and Herzegovina). The prevalence of testing HIV
positive was calculated, and 95% and 99% confidence intervals are shown. Logistic regression
was used to determine factors associated with testing HIV positive. Due to small numbers test-
ing or testing HIV-positive, we combined malignant lymphoma, anal dysplasia/cancer; hepati-
tis B+C, seborrheic dermatitis/exanthema, peripheral neuropathy of unknown cause, primary
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lung cancer and severe or recalcitrant psoriasis into one ‘other’ category and used pneumonia
as the reference category as the largest group (excluding the IMS extension). In sensitivity anal-
yses, the prevalence of testing HIV-positive was assessed separately in the IMS extension, and
after excluding data from the three largest sites.
A priori, the interaction between region and indicator conditions was of interest and for-
mally tested. In this analysis, due to the low numbers of individuals from Southern, Central
and Northern Europe, these regions were combined and compared to Eastern Europe, and
only ICs with more than 30 HIV positive results were considered (pneumonia, IMS and hepa-
titis B and C combined where those testing for hepatitis B alone, hepatitis C alone and both
hepatitis B and C were combined into a single group).
Logistic regression was also used to determine the factors associated with late presentation
for HIV, defined as a CD4 count� 350 cells/mm3 at the time of HIV diagnosis [8]. Forward
selection was used for this latter model, with p<0.1 as the entry criteria, with the exception of
including region and indicator conditions as variables of interest. In both logistic regression
analyses, the largest categories were chosen as the reference groups and some categories were
combined due to small numbers of individuals testing HIV positive. All ICs with fewer than 10
individuals testing HIV positive were combined to give the ‘other’ category.
Data on CD4 count, disease stage and linkage to care were collected for those with a confirmed
HIV diagnosis where available. Not all centres were able to retrieve this information as, on receipt
of a positive test result, many individuals transferred their care to an HIV treatment service. This
separation of services presented barriers to obtaining subsequent clinical information in some
instances. We have analysed linkage to care for individuals with data available and again treating
missing data as failure of linkage to care. Linkage to care was defined as a patient being seen for
specialist HIV care after diagnosis with date of first CD4 count being a proxy for first clinic visit,
while treatment initiation was defined as the date of starting antiretrovirals as reported by clinic.
Time taken for linkage to occur (measured as time between date of HIV diagnosis and date of
first CD4 count) was considered prompt when this was less than three months (<91 days) [9]. As
many of the sites recruiting people into the study were non-traditional HIV testing sites, the feasi-
bility and clinical safety of both testing and linkage to care was important to investigate in order
to address concerns regarding reduced or delayed access to treatment and care.
All analyses were performed using SAS (Statistical Analysis Software version 9.4).
Results
Patient characteristics
Of 11,663 potentially eligible individuals, 10,877 were included in the analysis (93.3%); of the
786 who were excluded, 671 were outside the age range, 68 had no IC information, 30 had no
HIV test result, 11 were missing the date of their HIV test and 6 had missing gender. The IMS
extension accounted for 1,111 (10.2%) eligible individuals.
Table 1 shows the participant’s characteristics overall and stratified by region; of the 10,877
individuals, 576 (5.3%) were from Southern Europe and 1,006 (9.2%), 2,822 (25.9%) and 6,473
(59.5%) were from Central, Northern and Eastern Europe respectively. There was considerable
heterogeneity between regions; Eastern Europe participants were more likely to be younger,
white Caucasians, less likely to have ever tested for HIV and more likely to have tested in an
in-patient setting (p<0.0001).
HIV prevalence
In total, 303 individuals tested HIV positive (2.8%; 95% confidence interval [CI] 2.5–3.1%).
The proportion testing positive varied between regions, it was greater in Southern Europe
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(n = 27, 4.7%; 95% CI 3.0–6.4%), followed by Eastern Europe (n = 223, 3.4%; 95% CI 3.0–
3.9%), Northern Europe (n = 41, 1.5%; 95% CI 1.0–1.9%) and lowest in Central Europe
(n = 12, 1.2%, 95% CI 0.5–1.9%). The rates for different ICs are shown in Fig 1 and was highest
for hepatitis B and C co-infection (9.7%; 95% CI 2.9–16.6%), albeit with wide confidence inter-
vals reflecting the comparatively small size of this group, followed by IMS (4.8%; 95% CI 3.9–
5.8%). Two ICs had no new HIV diagnoses; anal dysplasia/cancer and primary lung cancer.
The lower limit of the 95% confidence interval exceeded 0.1% for all ICs, except for anal dys-
plasia/cancer, primary lung cancer, peripheral neuropathy and psoriasis. Two additional ICs,
malignant lymphoma and seborrheic dermatitis/exanthema had lower 99% confidence limits
below 0.1%.
Fig 2 shows the association between IC’s, region and testing HIV positive after adjustment
for other factors. Compared to Eastern Europe, individuals from both Central and Northern
Europe had lower odds of testing positive, while those from Southern Europe were more likely
to test positive, although this was marginally statistically significant. Compared to pneumonia,
those presenting with IMS, lymphadenopathy and leukocytopenia/ thrombocytopenia were
more likely to test HIV positive, although this was marginally statistically significant for leuko-
cytopenia/ thrombocytopenia, while those presenting with cervical cancer, hepatitis B alone,
and the combined group of ‘Other IC’ (malignant lymphoma, anal dysplasia/cancer, both hep-
atitis B and C (acute and chronic), seborrheic dermatitis/ exanthema, peripheral neuropathy,
primary lung cancer and psoriasis) were less likely to test HIV-positive, although this was mar-
ginally statistically significant for cervical cancer.
In a pre-planned analysis, we found differences between regions (East vs South, Central and
North combined) and the odds of testing HIV-positive varied according to the three most
common ICs (global p<0.0001, test for interaction). We therefore repeated the analysis strati-
fied by IC’s. For pneumonia and hepatitis B and C combined, individuals from Eastern Europe
were more likely to test HIV-positive compared to the other regions (adjusted odds ratio
Table 1. Characteristics of included participants stratified by region.
All South Central North East P
N % N % N % N % N %
All 1087710877 100100 576576 5.35.3 10061006 9.29.2 28222822 25.925.9 64736473 59.559.5
Gender Male 58595859 53.953.9 311311 54.054.0 592592 58.858.8 14091409 49.950.1 35473547 54.845.2 <0.0001
Female 50185018 46.146.1 265265 46.046.0 414414 41.241.2 14131413 50.162.8 29262926 45.254.8
Ethnicity Caucasian 93679367 86.186.1 481481 83.583.5 682682 67.867.8 17721772 62.811.7 64326432 99.40.2 <0.0001
Asian 376376 3.53.5 1212 2.12.1 1919 1.91.9 329329 11.78.7 1616 0.20.0
African 344344 3.23.2 77 1.21.2 9191 9.09.0 245245 8.716.9 11 0.00.4
Unknown 790790 7.37.3 7676 13.213.2 214214 21.321.3 476476 16.920.4 2424 0.410.1
Setting Outpatient 48634863 44.744.7 244244 42.442.4 475475 47.247.2 18891889 66.916.5 22552255 34.850.0 <0.0001
In patient 41814181 38.438.4 244244 42.442.4 235235 23.423.4 465465 16.516.3 32373237 50.00.2
Prim. care 688688 6.36.3 7272 12.512.5 147147 14.614.6 459459 16.30.3 1010 0.215.0
Unknown 11451145 10.510.5 1616 2.82.8 149149 14.814.8 99 0.30.0 971971 15.00.0
Median IQR Median IQR Median IQR Median IQR Median IQR
Age Years 36 26–48 39 30–51 41 31–52 38 29–51 33 26–44 <0.0001
Date Mm/yy 7/13 1/13–2/14 6/13 11/12–2/14 8/13 12/12–1/14 9/13 3/13–4/14 6/13 1/13–1/14 <0.0001
Age calculated at date of blood sample date. IQR; interquartile range. P-value from chi-squared test for categorical variables and Wilcoxon test for continuous variables.
Prim. Care; primary care. Mm/yy; calendar month and year.
https://doi.org/10.1371/journal.pone.0220108.t001
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[aOR] 2.06; 95% CI 0.87–4.86 and 1.56; 95% CI 0.69–3.52 respectively). The opposite was seen
for IMS, where individuals from Western Europe were less likely to test positive compared to
other regions combined (aOR 0.87; 95% CI 0.40–1.88). These regional variations may reflect
differences in the structure of the local health system, IC management and health seeking
behaviours in addition to any true variation.
Characteristics of those testing HIV positive and potential missed
opportunities for earlier HIV testing
The median CD4 count at diagnosis, available for 268/303 (88.4%) was 230 cells/mm3 (IQR
95–430 cells/mm3) with no significant differences between regions (p = 0.15, table in S1
Table); the highest median CD4 count at diagnosis was seen in Northern Europe and lowest in
Southern Europe. Of these 178 (66.4%) would be classified as late presenters based on CD4
count alone, and was highest in Eastern Europe, followed by South, Central, and Northern
Europe respectively (p = 0.019). The median viral load (VL) at diagnosis (available for 265
individuals; 87.5%), was 5.2 log10copies/ml (IQR 4.6–5.8 log10copies/ml) with no significant
differences between regions (p = 0.22) or when comparing the proportion with a high viral
load (VL�100,000 copies/ml, p = 0.60).
Fig 1. Prevalence of testing HIV positive: HIDES II study.
https://doi.org/10.1371/journal.pone.0220108.g001
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Of the 293 individuals who provided information on previous HIV-associated symptoms
193 (65.9%) reported no symptoms (10 had missing data). Minor symptoms reported included
infectious mononucleosis-like syndrome in 15, oral candidiasis in 35, herpes zoster in 15,
unexplained leukocytopenia/ thrombocytopenia in 17 and seborrheic dermatitis in 15. Of the
223/294 individuals who provided information on previous STIs, 223 (75.9%) reported no
prior STI in the past 5 years. Reported STIs included gonorrhoea (12), syphilis (11), other
ulcerative genital conditions (12), chlamydia (11) and unspecified (36). Of the 280 individuals
with available data on hospital admissions in the 5 years prior to their HIV diagnosis, 53
(18.9%) had been hospitalised. Twenty-five (47%) of these admissions were associated with an
AIDS defining illness: herpes (chronic/extra-genital (5), recurrent bacterial pneumonia (4),
oesophageal candidiasis (4), pulmonary tuberculosis (3), pneumocystis pneumonia (3), and
one each of progressive multifocal leukoencephalopathy, non-Hodgkin’s lymphoma, recurrent
salmonella, toxoplasmosis, histoplasmosis and cervical cancer. Twenty-three of those admitted
reported other serious diagnoses, including pneumonia (13), endocarditis (3), bacteraemia (2),
cervical dysplasia (2) and one each of lung, anal and breast cancer.
A total of 166 (54.8%) of those testing HIV positive reported a previous hospital admission
for an AIDS defining illness, other serious illness, testing for HBV or HCV, or a diagnosed
STI, representing opportunities for earlier testing and potential diagnosis of HIV.
Fig 2. Adjusted odds of testing HIV positive.
https://doi.org/10.1371/journal.pone.0220108.g002
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Infectious mononucleosis-like syndrome
The prevalence of HIV infection among those testing for IMS was consistently high across all
regions; being highest in Southern Europe (9/89, 10.1%; 95% CI 1.7–18.5), followed by Eastern
Europe (66/1169; 5.6%, 95% CI 4.3–7.0), Central Europe (2/61; 3.3%, 95% CI 0–7.7) and lowest
in Northern Europe (22/729; 3.0%; 95% CI 1.8–4.3), with comparatively few individuals
included from Central Europe.
Among those testing HIV positive, there were 61 individuals who reported a previous HIV
test; of these, 11 (18.0%) were tested in 12 months preceding the positive test result. The pro-
portion of those reporting a negative HIV test in the previous 12 months was greatest for IMS
(10/31 32.3%), with only one person from all other ICs combined reporting a negative HIV
test in the previous 12 months (1/30 3.3%), p = 0.00057.
Linkage to care
Data on linkage to care and treatment initiation were reported for 176/303 (58.1%) individuals
who tested HIV positive. Applying our definition, of those with available data, 163/176
(92.6%) were classified as being promptly linked to care and 6 (3.4%) as experiencing delayed
linkage to care; for 7 there was no information available. Treating missing data as failure to
link to care decreases the proportion successfully transferred to care to 53.8%.
Four (2.5%) of those promptly linked to care were subsequently recorded as lost to follow-up
(LTFU) and 13 (8.0%) were recorded as having died within 12 months of diagnosis, giving a total
of 17/163 (10.4%) of individuals with prompt linkage to care who were LTFU or dead within 12
months after diagnosis. Of these 17, 15 had information on CD4 count and 14 (93.3%) were diag-
nosed at a late stage; 3 of the 4 LTFU (95.0%) and 11 of those who died (100.0%).
Sensitivity analysis
The analyses were repeated excluding the three largest sites (one each from Ukraine, Bosnia
and Herzegovina, and the UK) to determine the extent to which data from the largest centres
were explaining our findings. This analysis included 6,187 individuals (56.9%); of whom 159
tested HIV positive (rate 2.6%; 95% CI 2.2–3.0%). In a separate analysis, excluding just the
IMS extension limited the analysis to 9,766 persons, produced an HIV prevalence of 2.6%
(95% CI 2.3–3.0%), and a prevalence rate for IMS of 5.8% (54/937; 95% CI 4.3–7.3%). Results
from both sensitivity analyses were very similar to our overall findings.
Discussion
HIV prevalence and regional differences
The HIDES study confirms a greater than 0.1% HIV prevalence in people presenting with cer-
tain ICs and confirms the feasibility of this testing strategy across Europe [1, 10–11]. The Guid-
ance document on implementing IC guided HIV testing in healthcare settings in Europe [4]
has three categories of ICs, where Category 2 is divided between those conditions associated
with a confirmed undiagnosed HIV prevalence of>0.1% and thus testing is strongly recom-
mended (2a), and those conditions considered likely to have this prevalence, but without
proven evidence and hence testing should be offered (2b). Based on the results of this study,
two more conditions; unexplained lymphadenopathy and community acquired pneumonia
should be moved from the offer of a test to strongly recommending testing. The dissemination
of the updated table of ICs is important and for highest impact could be specifically directed
towards specialties involved in the treatment of these particular conditions, for example respi-
ratory/pulmonology, haematology and internal medicine, as well as general practitioners.
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Most HIV testing guidelines already recommend routine testing for specific at-risk popula-
tions, for example people who inject drugs (PWID), men who have sex with men (MSM),
some ethnic groups; IC guided HIV testing should be incorporated as an additional part of a
national strategy to improve testing offer in health care facilities. This approach has the benefit
of being opportunistic; relying on the attendance of the individual for another health-related
concern and hence does not require self-identification of risk or interventions by the health
service to ‘reach’ them. It further normalises HIV testing with routine offer to all those present-
ing with the IC and is therefore not based on personal characteristics or behaviours, which can
be both personally stigmatising and present barriers to health care professionals.
The proportion of individuals testing HIV-positive varied between regions, being higher in
Southern and Eastern Europe and lower in Northern and Central regions. These differences
are likely to be due to a combination of higher underlying HIV prevalence, higher levels of late
diagnosis, differences in health care systems and settings were testing was performed and the
ICs targeted in the respective regions.
Late diagnosis and missed opportunities for earlier HIV testing
The proportion of individuals diagnosed HIV positive with a CD4 count less than 350 cells/uL
was less than 50% only for IMS. In all other conditions the proportion of late presenters was
greater than 75%, reflecting the opportunity IMS affords for earlier diagnosis with less poten-
tial for immunological damage.
The study observed a consistently high HIV prevalence for people presenting with IMS and
considerably higher than the 0.1% cost-effectiveness cut-off, highlighting that routine HIV test-
ing in this group represents a very effective HIV case finding strategy. It is likely in this scenario
that the IMS presentation represents acute HIV sero-conversion; this is supported by the fact
that 32.3% of these diagnoses had an HIV-negative test in the 12 months prior to diagnosis. The
effect of introducing routine testing in people presenting with IMS has significant potential
impact for both individual and public health in terms of avoiding harm (reducing late diagno-
sis) and minimising the risk of onward transmission (access to Treatment as Prevention). Only
half of those testing positive had a low CD4 cell count at diagnosis; in those who had a low
count it is likely this was—in a significant number—due to the reversible fall in CD4 cell counts
associated with seroconversion. Given all these factors it is especially important that these indi-
viduals should be offered HIV testing and strategies and guidelines need to emphasise this.
Linkage to care
Data on linkage to care and treatment initiation were reported for 58.1% of those testing posi-
tive. The high level of missing data is likely to be due to the testing and study reporting taking
place in non-HIV settings and the difficulty obtaining clinical data about subsequent medical
attendances from HIV services. Whilst we cannot make assumptions about the individuals
with missing data, the lack of clinical data accessible to a testing site is of concern as engage-
ment in care is a key element of the effective monitoring of a testing programme.
Where we have data available our rates for linkage to care exceed 90% and occurs in a
timely fashion; this is higher than that reported elsewhere [12–14]. If missing data is treated as
failure to transfer to care this fall to 54%. It is probable the true proportion lies somewhere
between. Of those reported as being promptly linked to care 10.4% were reported to be either
LTFU or dead within 12 months of diagnosis. All of those who died had a low CD4 count at
diagnosis.
The location of the initial testing is likely to strongly influence the accessibility of subse-
quent clinical data by the testing service. Physical, organisational and specialty separation may
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all play a part, alongside the lack of clinical utility to the test originator. The outcome is not
known for 42% of those testing positive and suggests services lack clear mechanisms to ensure
transfer to care has occurred and is documented, with appropriate interventions if it has not
taken place.
The fact that data on linkage to care and treatment initiation were only available for 58% of
those testing positive, underlines the importance of improved monitoring of linkage to care
when testing is introduced in “non-HIV” settings, be it hospital department or general practi-
tioners as in this study or community-based settings. Testing services need to establish robust
mechanisms to confirm timely transfer to care with appropriate interventions when this fails
to occur.
Implementation
The ICs confirmed in the HIDES study should be adopted into European and national HIV
testing and IC specialty guidelines. Specific focus should be on specialty guidelines, for
example respiratory/pulmonology, haematology and internal medicine, many of which fre-
quently do not include recommendations for HIV testing in ICs [15] despite evidence to
support the cost effectiveness of testing in these situations. Given the delivery of these pro-
grammes are frequent in departments unused to delivering a safe, effective HIV testing pro-
gramme implementation tools, including those for training and education, can support its
introduction and spread. Such tools have been developed through the EU-co-funded project
OptTEST [16] and will be further supported through the EU co-funded INTEGRATE Joint
action [17].
IC guided HIV testing strategy should be incorporated into guidelines to supplement the
current recommendations which mainly focus on testing specific at-risk groups (PWID,
MSM) and in certain settings (e.g. sexual health services). Both these strategies require either
self-identification of risk and an individual acting on this to present for testing or being asked
about possible risks (or assumptions made); additional resources are often required if services
are to ‘reach’ out to many of these groups. Whilst effective to a degree these approaches have
to date been insufficient to address the epidemic and additional strategies are required. IC
guided HIV testing has a number of advantages to contribute; normalisation of HIV testing,
reduced stigmatisation, opportunistic nature with reduced associated costs and being indepen-
dent of the requirement for individual or health care worker to carry out a risk assessment.
Limitations
There are a number of potential limitations to our study. As we do not report risk group data
and test offer and offer outcome we cannot exclude the potential bias of targeted offer of test-
ing based on belonging to a risk group. Most services had no mechanism and limited capacity
to capture test offer and outcome, however other studies have reported high acceptance rate of
HIV test offer across a variety of healthcare settings[6]. Furthermore, we are unable to report
denominator data for total number of patients attending for management of the specific IC;
this was not an objective of this study, but as reported elsewhere [6] coverage is generally low
across most ICs, apart from TB and some AIDS defining conditions in some regions. All ICs
were not offered uniformly across the region and this again may introduce bias by different
services in different regions having variation in the risk profiles of those who attend. Transfer-
ability cannot be assumed as many of those involved are already advocates of HIV testing and
coverage may be less complete if rolled out to less engaged clinicians. Finally, recall bias may
have affected reporting of previous potential HIV related symptoms and illnesses and under-
estimated missed opportunities for earlier diagnosis.
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Conclusion
The HIDES II study confirms IC status for two important and common conditions; lymphade-
nopathy and pneumonia. Within the study HIV testing in 10 conditions demonstrated HIV
prevalences exceeding > 0.1%. This was not demonstrated for the remaining four conditions;
neuropathy, psoriasis, anal cancer and lung cancer, as relatively low numbers of patients were
tested and there were few events; further work is required for these conditions. As infectious
mononucleosis-like syndrome can mimic acute HIV sero-conversion illness and has the high-
est HIV prevalence, this IC in particular affords opportunities for earlier HIV diagnosis and
transmission interruption. We would therefore recommend these ICs to be included in Euro-
pean and national HIV testing and IC specialty guidelines. Further work is required to support
implementation of IC driven HIV testing as this strategy has the potential to significantly
impact on undiagnosed HIV and late diagnosis with well recognised associated individual and
public health benefits.
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